182 related articles for article (PubMed ID: 36117308)
1. Circulating Methylated SEPT9 DNA Analyses to Predict Recurrence Risk and Adjuvant Chemotherapy Benefit in Stage II to III Colorectal Cancer.
Yuan Z; Wang S; Ni K; Zhan Y; Ma H; Liu X; Xin R; Zhou X; Liu Z; Zhao X; Yin X; Ping H; Liu Y; Wang W; Yan S; Han Q; Cui W; Zhang X; Zhang Q; Zhang C
Med Sci Monit; 2022 Sep; 28():e937757. PubMed ID: 36117308
[TBL] [Abstract][Full Text] [Related]
2. Performance of circulating methylated Septin9 gene DNA in diagnosis and recurrence monitoring of colorectal cancer in Western China.
Gao JJ; Wang YW; Li Y; Wang ZL; Feng A; Li N; Hui LY
Clin Chim Acta; 2022 Dec; 537():118-126. PubMed ID: 36330944
[TBL] [Abstract][Full Text] [Related]
3. Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer.
Fu B; Yan P; Zhang S; Lu Y; Pan L; Tang W; Chen S; Chen S; Zhang A; Liu W
Dis Markers; 2018; 2018():6437104. PubMed ID: 29849824
[TBL] [Abstract][Full Text] [Related]
4. Methylated septin 9 gene is an important prognostic marker in stage II and stage III colorectal cancer for evaluating local recurrence or distant metastasis after surgery.
Huang M; He J; Lai W; Liu L; Xu H; Zeng Y; Lan Q; Lin X; Chu Z
BMC Gastroenterol; 2022 Feb; 22(1):87. PubMed ID: 35227194
[TBL] [Abstract][Full Text] [Related]
5. Methylated Septin 9 as a Promising Biomarker in the Diagnosis and Recurrence Monitoring of Colorectal Cancer.
Lu P; Zhu X; Song Y; Luo Y; Lin J; Zhang J; Cao Y; Huang Z
Dis Markers; 2022; 2022():7087885. PubMed ID: 35818587
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic Value and Clinical Significance of Methylated SEPT9 for Colorectal Cancer: A Meta-Analysis.
Hu J; Hu B; Gui YC; Tan ZB; Xu JW
Med Sci Monit; 2019 Aug; 25():5813-5822. PubMed ID: 31378778
[TBL] [Abstract][Full Text] [Related]
7. Detection of methylated septin 9 in tissue and plasma of colorectal patients with neoplasia and the relationship to the amount of circulating cell-free DNA.
Tóth K; Wasserkort R; Sipos F; Kalmár A; Wichmann B; Leiszter K; Valcz G; Juhász M; Miheller P; Patai ÁV; Tulassay Z; Molnár B
PLoS One; 2014; 9(12):e115415. PubMed ID: 25526039
[TBL] [Abstract][Full Text] [Related]
8. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
[TBL] [Abstract][Full Text] [Related]
9. Clinical value of preoperative methylated septin 9 in Chinese colorectal cancer patients.
Yang X; Xu ZJ; Chen X; Zeng SS; Qian L; Wei J; Peng M; Wang X; Liu WL; Ma HY; Gong ZC; Yan YL
World J Gastroenterol; 2019 May; 25(17):2099-2109. PubMed ID: 31114136
[TBL] [Abstract][Full Text] [Related]
10. Methylated Septin9 identified patients with colorectal carcinoma and showed higher sensitivity than conventional biomarkers in detecting tumor.
Leerhoff S; Raem A; Kolbe EW; Schulz L; Borchers K; Köhler T; Winde G; Kirchner C
Cancer Treat Res Commun; 2023; 36():100748. PubMed ID: 37541105
[TBL] [Abstract][Full Text] [Related]
11. Role of blood mSEPT9 in evaluating tumor burden and disease monitoring in colorectal cancer patients.
Jiang H; Yu Q; Chen X; Zhang C; Shen J; Shen M; Yang Y; Wang B; Pan B; Guo W
J Clin Lab Anal; 2021 Nov; 35(11):e24030. PubMed ID: 34591323
[TBL] [Abstract][Full Text] [Related]
12. Detection of Methylated SEPT9 in Korean Colorectal Cancer Patients: Comparison with Previous Studies.
Kim H; Lee JK; Hong YJ; Moon SM; Shin US; Kwon H; Shin K; Chang YH
Clin Lab; 2018 Sep; 64(9):1573-1579. PubMed ID: 30273999
[TBL] [Abstract][Full Text] [Related]
13. The value of serum methylated septin 9 and carcinoembryonic antigen in efficacy evaluation and follow-up monitoring of colorectal cancer.
Gao H; Zhu ZQ; Wusiman L; Wujieke A; Zhang WB
Ann Ital Chir; 2023; 94():384-391. PubMed ID: 37794798
[TBL] [Abstract][Full Text] [Related]
14. Methylated Septin9 has moderate diagnostic value in colorectal cancer detection in Chinese population: a multicenter study.
Lu DC; Zhang QF; Li L; Luo XK; Liang B; Lu YH; Hu BL; Jiang HX
BMC Gastroenterol; 2022 May; 22(1):232. PubMed ID: 35546391
[TBL] [Abstract][Full Text] [Related]
15. Distinct Performance of Methylated
Tang H; Ma X; Zhou L; Li W; Shu Y; Xu H; Li J; Wang F; Sun F; Duan Y
Genet Test Mol Biomarkers; 2022 Apr; 26(4):239-248. PubMed ID: 35481971
[No Abstract] [Full Text] [Related]
16. mSEPT9 Can Monitor the Response and Predict the Prognosis of Stage IV Colorectal Cancer Patients with Liver Metastasis Undergoing Potentially Curative Surgery.
Liu W; Hu P; Liu J; Chen L
J Surg Res; 2021 Nov; 267():485-494. PubMed ID: 34246842
[TBL] [Abstract][Full Text] [Related]
17. Circadian Rhythm of Methylated Septin 9, Cell-Free DNA Amount and Tumor Markers in Colorectal Cancer Patients.
Tóth K; Patai ÁV; Kalmár A; Barták BK; Nagy ZB; Galamb O; Wichmann B; Tulassay Z; Molnár B
Pathol Oncol Res; 2017 Jul; 23(3):699-706. PubMed ID: 28035516
[TBL] [Abstract][Full Text] [Related]
18. Methylated Septin9 (m
Loomans-Kropp HA; Song Y; Gala M; Parikh AR; Van Seventer EE; Alvarez R; Hitchins MP; Shoemaker RH; Umar A
Cancer Res Commun; 2022 Feb; 2(2):90-98. PubMed ID: 35992328
[TBL] [Abstract][Full Text] [Related]
19. Recurrence risk assessment for stage III colorectal cancer based on five methylation biomarkers in plasma cell-free DNA.
Wang W; Zhu X; Zhang X; Lei C; Zeng Z; Lan X; Cui W; Wang F; Xu S; Zhou J; Wu X; Deng H; Li X; Fan J; Ding Y; Huang Z; Liang L
J Pathol; 2023 Apr; 259(4):376-387. PubMed ID: 36573552
[TBL] [Abstract][Full Text] [Related]
20. The role of
Sun J; Fei F; Zhang M; Li Y; Zhang X; Zhu S; Zhang S
BMC Cancer; 2019 May; 19(1):450. PubMed ID: 31088406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
